View Older Stories View More Recent Stories
-
UniQure faces FDA setback on Huntington's disease gene therapy
-
uniQure BV (QURE) PT Raised to $110 at H.C. Wainwright
-
uniQure BV (QURE) PT Raised to $95 at Guggenheim
-
uniQure BV (QURE) PT Raised to $80 at Cantor Fitzgerald
-
uniQure BV (QURE) PT Raised to $80 at Cantor Fitzgerald
-
Bristol Myers Squibb expands direct-to-patient drug sales program
-
Mizuho Upgrades uniQure BV (QURE) to Outperform
-
uniQure BV (QURE) PT Raised to $65 at Wells Fargo
-
uniQure BV (QURE) PT Raised to $60 at Mizuho
-
Goldman Sachs Reiterates Neutral Rating on uniQure BV (QURE)
-
uniQure BV (QURE) PT Raised to $68 at Leerink, 'topline results from the pivotal Phase 1/2 study of AMT-130 in Huntington's disease (HD) as a definitive win'
-
TD Cowen Reiterates Buy Rating on uniQure BV (QURE)
-
uniQure BV (QURE) PT Raised to $65 at Stifel
-
Stifel on uniQure BV (QURE): 'AMT-130 3yr data in Huntington's Disease exceeded our expectations'
-
uniQure (QURE) to Resume Trading at 7:35 a.m.
-
uniQure secures $175 million debt facility from Hercules Capital
-
uniQure reports positive AMT-130 trial results for Huntington's disease
-
uniQure (QURE) Halted, News Pending
-
Cantor Fitzgerald Reiterates Overweight Rating on uniQure BV (QURE)
-
Mizuho says buy uniQure BV (QURE) on weakness
-
H.C. Wainwright Reiterates Buy Rating on uniQure BV (QURE)
-
uniQure reports enzyme increases in Fabry disease gene therapy trial
-
Mizuho Upgrades uniQure BV (QURE) to Outperform
-
uniQure (QURE) defended at Mizuho
-
uniQure (QURE) Tops Q2 EPS by 20c
-
uniQure (QURE) spreader of 2500 contracts of October 15 and 30 calls
-
Stifel on uniQure BV (QURE): 'we are optimistic that the upcoming 3-year AMT-130 analysis is likely to look strong'
-
uniQure (QURE) Appoints Kylie O’Keefe as Chief Customer and Strategy Officer
-
FDA Cell and Gene Therapy Roundtable 'bullish for the space' - Stifel
-
Stifel Reiterates Buy Rating on uniQure BV (QURE)
-
H.C. Wainwright Reiterates Buy Rating on uniQure BV (QURE)
-
uniQure (QURE) Provides Regulatory Update on AMT-130 for Huntington’s Disease
-
H.C. Wainwright Reiterates Buy Rating on uniQure BV (QURE)
-
uniQure (QURE) Tops Q1 EPS by 18c
-
H.C. Wainwright Reiterates Buy Rating on uniQure BV (QURE)
-
Increasing unusual call option volume: XND HTZ QURE KEY TMC CAR ALHC GPN AGL HDB IBN
-
uniQure (QURE) Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease
-
Chardan Capital Markets Assumes uniQure BV (QURE) at Buy, PT $38
-
H.C. Wainwright Reiterates Buy Rating on uniQure BV (QURE)
-
uniQure (QURE) Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the
-
uniQure (QURE) Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II Trial of AMT-162
-
H.C. Wainwright Reiterates Buy Rating on uniQure BV (QURE)
-
uniQure (QURE) Prices 4.41M Share Offering at $17/sh
-
uniQure (QURE) Announces Proposed Share and Warrant Offering
-
uniQure (QURE) Files Mixed Shelf
-
7 top biotech picks for 2025 according to Wells Fargo
-
TD Cowen: '10 Potential "Thome Run" Catalysts to Watch in 2025'
-
uniQure BV (QURE) PT Raised to $20 at Mizuho
-
uniQure BV (QURE) PT Raised to $20 at RBC Capital as 'FDA Leniency Materially De-risks HD'
-
Goldman Sachs Reiterates Neutral Rating on uniQure BV (QURE)
